An existing drug has shown that it can greatly improve the quality of sleep for those suffering from obstructive sleep apnea (OSA). It also boosts weight loss and heart health.
Tirzepatide was so successful that many trial participants were able to stop using their specialist CPAP machines. It looks promising that the drug could be the first to effectively treat the condition that affects an estimated 936 million people worldwide.
In a study of just under 500 participants with OSA and weight issues, researchers from the University of California San Diego's School of Medicine tested the use of tirzepatide to improve sleep and quality of life.
Currently, this drug is best known in treatment of type 2 diabetes and obesity, and is sold under the brand names Mounjaro and Zepbound.
"This study marks a significant milestone in the treatment of OSA, offering a promising new therapeutic option that addresses both respiratory and metabolic complications," said lead author of the study Atul Malhotra, MD, professor of medicine.
"Historically, treating OSA meant using devices during sleep, like a CPAP machine, to alleviate breathing difficulties and symptoms," Malhotra said. "However, its effectiveness relies on consistent use. This new drug treatment offers a more accessible alternative for individuals who cannot tolerate or adhere to existing therapies. We believe that the combination of CPAP therapy with weight loss will be optimal for improving cardiometabolic risk and symptoms. Tirzepatide can also target specific underlying mechanisms of sleep apnea, potentially leading to more personalized and effective treatment."
Comentarios